LCM
CBAY

LCM Capital Management’s Cymabay Therapeutics CBAY Stock Holding History

LCM Capital Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,000
Closed -$37K – 100
2021
Q3 		$37K Buy
+10,000
New +$39.4K 0.03% 88
2021
Q2 		– Sell
-10,000
Closed -$45K – 90
2021
Q1 		$45K Buy
+10,000
New +$53.8K 0.04% 85

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

LCM Capital Management's CBAY Position: Q4 2021 in Review

LCM Capital Management sold out of Cymabay Therapeutics (CBAY) in Q4 2021, closing a stake of 10,000 shares — an estimated $37K sold.

LCM Capital Management first reported a position in CBAY in Q1 2021 and held it in 2 quarters. The position peaked at $45K in Q1 2021. 113 funds tracked by Wall St. Rank hold CBAY as of Q4 2021.

  • LCM Capital Management reported no remaining Cymabay Therapeutics position as of Q4 2021 after selling out during the quarter.
  • LCM Capital Management sold 10,000 Cymabay Therapeutics shares in Q4 2021, an estimated $37K.
  • LCM Capital Management first reported a position in Cymabay Therapeutics in Q1 2021 and held it in 2 quarters.
  • LCM Capital Management's Cymabay Therapeutics position peaked at $45K in Q1 2021.
  • 113 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2021.

Based on LCM Capital Management's 13F filing for Q4 2021, filed 24 Jan 2022.